Replies to post #218214 on Biotech Values

[biotech_researcher]

RVNC /RT002 récent hires for EARLY LAUNCH. That sure crossed my mind, but the AGN hire puts in a different league. Well done Mr. Browne..

[DewDiligence]

Re: RVNC /RT002 launch timing (addendum)

Doesn't it seem more reasonable from an expense standpoint to hire the leaders of the commercial team 18 months prior to launch rather than two years prior to launch?

I asked some people in the know about these kinds of things, and the feedback I got is that 18 months prior to launch is very early, and two years prior to launch is unheard of.

Comments welcome.

[Bickema]

RVNC - my concern with Revance right now is how much more in value can shares appreciate before they have to start showing revenue and RT002 uptake?

With a market cap of roughly 1 billion and the obvious need for more funds, especially considering the new hires (which are very impressive), how much room is left for appreciation at this valuation?

Investors have time to wait for additional funding and proof of RT002 uptake IMO. As a long, I hope I am wrong but that is my bearish view as far as the next 12-16 months go.

[Bickema]

I don't have enough industry knowledge to weigh in but I do fancy your hypothesis and do think its quite reasonable.

If I remember correctly, didn't the FDA revise their botulinum toxin guidelines back in 2014 to encourage botox generics? I can't find the article

Anyway I find it encouraging that the new hires were willing to jump ship from very sucsessful, multibillion dollar companies that will surely be around for decades to come, to join Revance.

It also strengthens my perception that Dan Browne has no plans to buy time or coast off free shares and compensation. He is as serious as a heart attack at getting RT002 to market as soon as possible.

Question: How do these new hires affect your opinion on potential partnerships for RT002?